Overview
This trial evaluates the effects (e.g. on quality of life, weight) of NORTASEĀ® compared to standard care of patients who have undergone gastrectomy.
Eligibility
Inclusion Criteria:
- Gastrectomy (total and partial)
- Age 18 or older
- Written informed consent
Exclusion Criteria:
- Indication for pancreas enzyme therapy
- Gastrectomy with palliative intention
- UICC (Union for International Cancer Control) Stage IV gastric malignancy
- Malnutrition of other aetiology
- Life expectancy < 12 months
- Known lactose intolerance
- Known hereditary galactose intolerance
- Patients on alpha-glucosidase inhibitors (AGIs)
- Acute pancreatitis
- Acute episode of chronic pancreatitis
- Known hypersensitivity to moulds (mould allergy) or any other ingredient of NORTASEĀ®
- Participation in competing interventional trials may be allowed under circumstances
- Patients under legal supervision or guardianship
- Patients who are dependent on the investigator or the medical staff of the trial team or the coordinating investigator or the sponsor
- Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial
- Pregnant or nursing women
- Suspected lack of compliance
- Patients who were already enrolled in the trial